Morphocell Technologies

About Morphocell Technologies

Morphocell Technologies is a preclinical regenerative medicine company developing cell therapies and engineered tissues to treat severe organ deficiencies, with an initial focus on liver failure. The company was founded in 2018 by Dr. Massimiliano Paganelli and Dr. Claudia Raggi, evolving from research that began in 2016 at Centre Hospitalier Universitaire Sainte-Justine to find alternatives to liver transplants for pediatric patients. Dr. Paganelli, the CEO, is a pediatric transplant hepatologist, and Dr. Raggi, the CSO, is an expert in human development and stem cell differentiation.

The company's core product is ReLiver®, a therapy platform based on implantable, stem cell-derived liver tissue. This allogeneic treatment is designed for acute, chronic, and acute-on-chronic liver failure. The transient implantation of ReLiver® aims to improve survival, accelerate the recipient's own liver regeneration, and treat hepatic encephalopathy, all without requiring immunosuppressant drugs. The platform uses induced pluripotent stem cells (iPSCs) to generate functional liver tissue.

Morphocell operates on a business model focused on advancing its therapeutic pipeline through to clinical trials and eventual commercialization. The company is supported by significant venture capital investment, having completed a US$50 million Series A financing round in 2025. This funding provides an operational runway of over three years to advance the ReLiver® program toward clinical proof-of-concept, expand manufacturing capabilities, and support global expansion. The company is headquartered in Montreal, Canada, with offices in Toronto, Cambridge (Massachusetts), and a new subsidiary in Italy to enter the European market.